S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Bank Accounts: Frozen! (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Buy THIS stock before Taiwan is attacked (Ad)
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Bank Accounts: Frozen! (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Buy THIS stock before Taiwan is attacked (Ad)
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Bank Accounts: Frozen! (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Buy THIS stock before Taiwan is attacked (Ad)
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Bank Accounts: Frozen! (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Buy THIS stock before Taiwan is attacked (Ad)
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
NASDAQ:XGN

Exagen - XGN Stock Forecast, Price & News

$2.43
+0.01 (+0.41%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.35
$2.46
50-Day Range
$2.23
$2.87
52-Week Range
$2.04
$9.20
Volume
9,957 shs
Average Volume
25,918 shs
Market Capitalization
$40.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

Exagen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
167.5% Upside
$6.50 Price Target
Short Interest
Healthy
0.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.29
Upright™ Environmental Score
News Sentiment
0.36mentions of Exagen in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$15,658 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.87) to ($1.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.74 out of 5 stars

Medical Sector

66th out of 1,004 stocks

Medical Laboratories Industry

4th out of 24 stocks


XGN stock logo

About Exagen (NASDAQ:XGN) Stock

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Receive XGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter.

XGN Stock News Headlines

Exagen Inc. (NASDAQ:XGN) Short Interest Update
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.
Here's what Wall Street expects from Exagen's earnings
Exagen Inc. to Participate in Upcoming March Conferences
Exagen Inc. Reports Third Quarter 2022 Results
Exagen Announces Appointment of John Aballi as CEO
See More Headlines
Receive XGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter.

XGN Company Calendar

Last Earnings
11/10/2021
Today
4/01/2023
Next Earnings (Estimated)
5/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XGN
Phone
N/A
Fax
N/A
Employees
219
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.50
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+167.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-47,390,000.00
Pretax Margin
-104.62%

Debt

Sales & Book Value

Annual Sales
$45.56 million
Book Value
$2.61 per share

Miscellaneous

Free Float
10,281,000
Market Cap
$40.90 million
Optionable
Not Optionable
Beta
1.26

Key Executives

  • Mr. Kamal Adawi M.S. (Age 43)
    MBA, CFO & Corp. Sec.
    Comp: $609.62k
  • Mr. John Aballi (Age 37)
    CEO, Pres & Director
  • Ryan Douglas
    Investors Relations Officer
  • Mr. John Wegener (Age 53)
    Sr. VP of Sales and Marketing
  • Dr. Andrew L. Concoff FACR
    M.D., Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board
  • Mr. Mark Hazeltine (Age 48)
    Chief Bus. Officer













XGN Stock - Frequently Asked Questions

Should I buy or sell Exagen stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XGN shares.
View XGN analyst ratings
or view top-rated stocks.

What is Exagen's stock price forecast for 2023?

4 equities research analysts have issued twelve-month target prices for Exagen's stock. Their XGN share price forecasts range from $5.00 to $7.00. On average, they predict the company's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 167.5% from the stock's current price.
View analysts price targets for XGN
or view top-rated stocks among Wall Street analysts.

How have XGN shares performed in 2023?

Exagen's stock was trading at $2.40 at the beginning of 2023. Since then, XGN stock has increased by 1.3% and is now trading at $2.43.
View the best growth stocks for 2023 here
.

Are investors shorting Exagen?

Exagen saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 9,700 shares, a decline of 54.9% from the February 28th total of 21,500 shares. Based on an average daily volume of 23,400 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.1% of the company's stock are sold short.
View Exagen's Short Interest
.

When is Exagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our XGN earnings forecast
.

How were Exagen's earnings last quarter?

Exagen Inc. (NASDAQ:XGN) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.04. The business earned $12.25 million during the quarter, compared to the consensus estimate of $12.13 million. Exagen had a negative net margin of 98.11% and a negative trailing twelve-month return on equity of 70.16%. During the same quarter in the prior year, the company earned ($0.34) earnings per share.

What guidance has Exagen issued on next quarter's earnings?

Exagen issued an update on its first quarter 2023 earnings guidance on Tuesday, March, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $9.20 million-$9.70 million, compared to the consensus revenue estimate of $9.33 million.

What is Ron Rocca's approval rating as Exagen's CEO?

5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees.

When did Exagen IPO?

(XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO.

What is Exagen's stock symbol?

Exagen trades on the NASDAQ under the ticker symbol "XGN."

How do I buy shares of Exagen?

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exagen's stock price today?

One share of XGN stock can currently be purchased for approximately $2.43.

How much money does Exagen make?

Exagen (NASDAQ:XGN) has a market capitalization of $40.90 million and generates $45.56 million in revenue each year. The company earns $-47,390,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis.

How many employees does Exagen have?

The company employs 219 workers across the globe.

How can I contact Exagen?

Exagen's mailing address is 1261 Liberty Way Suite C, VISTA CA, 92081. The official website for the company is www.exagen.com. The company can be reached via email at ir@exagen.com.

This page (NASDAQ:XGN) was last updated on 4/1/2023 by MarketBeat.com Staff